Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus GLYCOPYRRONIUM TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus GLYCOPYRRONIUM TOSYLATE.
DICYCLOMINE HYDROCHLORIDE vs GLYCOPYRRONIUM TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
10-20 mg orally 3-4 times daily
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion.
Category A/B
Category C
Anticholinergic
Anticholinergic